Omeros Corp (OMER) stock is tumbling on Friday morning following a major regulatory setback in Europe that has caught investors off guard. Investors are bailing on OMER mostly because the European Medicines Agency’s (EMA) expert panel has rejected its primary commercial asset. At the time of writing, Omeros stock is down some 50% versus the
Moderna Inc. (MRNA) shares surged nearly 10% on Friday, extending a powerful rally that has lifted the stock about 40% over the past month and significantly outperformed the broader market. The gains followed the company’s Science Day presentation and investor event, where Moderna outlined an ambitious strategy to expand beyond its COVID-19 vaccine business and
Ripple has reported a sharp increase in tokenised assets issued on the XRP Ledger, highlighting growing institutional interest in blockchain-based financial products even as XRP continues to face pressure in the broader cryptocurrency market. The value of tokenised real-world assets (RWAs) on the XRP Ledger rose from about $5 million at the start of 2025
Apple Inc. (AAPL) shares have come under pressure after the company raised prices on several MacBook and iPad models. But some Wall Street analysts believe the pullback could present a buying opportunity as the company leverages its pricing power and loyal customer base. Apple stock fell 6.1% on Thursday after the company announced price increases
The Dow Jones Industrial Average and the broader US stock market closed lower on Friday as investors continued rotating out of technology and semiconductor stocks while shifting into more defensive sectors such as healthcare, consumer staples, and utilities. The S&P 500 slipped 0.27% to close at 7,337.68, while the Nasdaq Composite fell 0.48% to 25,236.88.
The artificial intelligence boom has long been pitched as a transformative force that would boost productivity and eventually lower costs across the economy. But this week, investors were confronted with a less discussed consequence of the AI race: higher prices. Apple and Microsoft both announced product price increases on Thursday, citing soaring costs for memory
A growing chorus of China’s most influential hedge fund managers is sounding the alarm on what they describe as a dangerously overheated global AI trade. After an explosive run-up in semiconductor and model‑development stocks from Seoul to Silicon Valley, several of Beijing’s money managers now argue the rally has detached from fundamentals – and that
Wall Street’s AI trade is heading into Friday with less confidence than it had 24 hours ago. Nasdaq futures led the decline as chip stocks gave back part of their Micron-driven rally, while investors again questioned whether the sector’s explosive gains have run ahead of earnings reality. The mood was not helped by reports that
China’s domestic technology initial public offering market is witnessing a strong recovery as Beijing steps up efforts to support listings by semiconductor and artificial intelligence (AI) companies. The renewed momentum comes as the country pursues technological self-reliance amid its ongoing rivalry with the United States. Technology companies have raised a combined $3.1 billion through stock
AAVE extended its weekly gains after Aave founder Stani Kulechov dismissed claims that the decentralized finance protocol planned to sell tokens at a steep discount while also confirming that a new automated buyback mechanism is under development. The token traded at $83.88 at the time of writing, up nearly 16% over the past seven days.